Author: Lexi Moore

How does MDM2 inhibition work to treat myeloproliferative neoplasms (MPNs)? What are the goals of this treatment approach? Renowned experts Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss MDM2 inhibition as an avenue for the treatment of MPNs and share information on an upcoming MDM2 clinical trial for patients living with myelofibrosis (MF) and polycythemia vera (PV). Who is this therapy right for? Watch now to find out more about the trial, eligibility, potential side effects and more. This program is sponsored by Kartos Therapeutics, Inc. This organization has no editorial control. It is produced solely by Patient Power. ...

Sierra Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2, and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis. "Fast Track designation for momelotinib highlights the serious and significant unmet needs of patients with myelofibrosis who have previously received a JAK inhibitor. These patients typically suffer from uncontrolled constitutional symptoms, progressively worsening anemia often resulting in transfusion dependence, and enlarged spleens. Fast Track also recognizes the absence of FDA-approved treatments for these patients and that momelotinib has the potential to address their unmet needs," said Dr. Barbara Klencke, Chief Development Officer of Sierra Oncology. "We look forward to continuing to work closely with the FDA as we launch and conduct the MOMENTUM Phase 3 trial of momelotinib, with the goal of bringing this important therapy to patients expeditiously." According to the FDA, "Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat...

Presented at the 24th Congress of the European Hematology Association (EHA), Imago BioSciences, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 1/2a clinical trial of a lysine-specific demethylase (LSD1) inhibitor, IMG-7289. Imago decided to expand the study into a Phase 2b trial and is evaluating clinical investigations in additional myeloid diseases. “IMG-7289 has shown tremendous promise to be a meaningful treatment option for myelofibrosis patients, and these data support our clinical program,” said Hugh Young Rienhoff, Jr. M.D., chief executive officer of Imago BioSciences. “These data, particularly the strong safety and efficacy signals, have informed our Phase 2b dosing strategy and encourage us to explore additional indications in myeloproliferative diseases." CLICK HERE TO READ THE FULL RELEASE. ...

Presented at the 24th Congress of the European Hematology Association (EHA), Promedior, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 2 study of PRM-151 in myelofibrosis (MF) patients who were ineligible for Ruxolitinib or had failed the drug. Promedior looks forward to advancing the clinical program for PRM-151 in both MF and will explore other fibrotic indications in the future. PRM-151 demonstrated promising antifibrotic activity as measured by a reduction in bone marrow fibrosis and improvement in hematologic measures. According to Dr. Srdan Verstovsek, Professor, Leukemia Department, MD Anderson Cancer Center. "Patients also showed a reduction in their myeloproliferative neoplasm symptoms, as well as a trend to prolonged survival with PRM-151 monotherapy in these refractory MF patients with great unmet need."  Click here to read the full release ...

Today the American Society of Clinical Oncology is wrapping up their 2019 ASCO meeting held annually in Chicago, IL. Although ASCO does not focus solely on blood cancers, the MPN Research Foundation looks forward to attending each year to discuss the status of MPN research and treatments with oncology professionals, drug companies, and fellow advocacy groups. Click the links below to read the abstracts and updates pertaining to MPN related science that was presented at ASCO 2019. ASCO 2019 Abstracts, Posters, Meeting Videos, and SlidesInterim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis PatientsFedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis. Stay tuned. The next conference with MPN news and updates will be at the annual American Society of Hematology conference in December 2019. ...

DATE: 25th to 27th October 2019LOCATION: LISBON, PORTUGAL Dear MPN AN advocate’s, Our Learn Share & Grow approach that can be achieved through collaboration and is the cornerstone for the advancement of MPN knowledge for our members.  The MPN Horizons conference is dedicated to the development of our members as patient advocates and deals with topics such as Psycho-Social issues, How MPN’s work on a Molecular level, how to be an effective Advocate, Pipeline for treatment and Living with an MPN. Dealing with these types of questions is the essence of Learn. Share & Grow and our conference offers the opportunity to support and facilitate the quality of education. This one of a kind conference also provides opportunities to be able to exchange ideas, interact & share best practice and provide a platform to start networking across borders, build alliances and so much more for you to bring back to your own organization.  The registration process will start on June 1, 2019, and we will inform you as soon as...

The 2018 global conference for MPN Patient Advocates was held from August 31st to September 2nd in Prague, the Czech Republic The event consisted of over 20 talks, covering updates on MPN Research, current and emerging therapies, symptom management and a variety of advocacy and support topics. Videos and slides from the presentations are available here. ...